Cost-utility analysis of taxane therapy

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

A cost-utility analysis of docetaxel versus paclitaxel in patients with anthracycline-resistant metastatic breast cancer was reviewed. Cost-utility analysis provides estimates of the additional cost of a new therapy per quality-adjusted life-year (QALY) saved or gained. Utility scores measure the strength of a patient's preference for a given health state or outcome. Few studies have evaluated preferences in patients receiving cancer treatment. Since docetaxel may represent an advance in the management of anthracycline- resistant recurrent metastatic breast cancer, a decision-analysis model was developed to evaluate the pharmacoeconomics of this drug versus those of paclitaxel. Although the overall treatment costs of docetaxel were slightly higher than those of paclitaxel, docetaxel was associated with a gain of 0.0905 QALY per patient. This gain in QALYs is equivalent to 33 days of perfect health, which represents a substantial proportion of the life expectancy of one of these patients (typically no longer than nine months). The incremental cost-utility ratio associated with docetaxel therapy was estimated to be $4011 per QALY. Compared with paclitaxel, docetaxel for anthracycline-resistant metastatic breast cancer is within the acceptable range of cost-effectiveness ratios for most medical interventions. Cost- utility analysis is a valuable technique for evaluating new antineoplastic regimens that offer some treatment benefit but do not prolong survival compared with other therapeutic options.

Original languageEnglish (US)
Pages (from-to)S11-S15
JournalAmerican Journal of Health-System Pharmacy
Volume54
Issue numberSUPPL. 2
StatePublished - Jan 1 1997

Fingerprint

docetaxel
Cost-Benefit Analysis
Quality-Adjusted Life Years
Paclitaxel
Anthracyclines
Patient Preference
Breast Neoplasms
Therapeutics
Costs and Cost Analysis
Pharmaceutical Economics
Decision Support Techniques
Health
Life Expectancy
Health Care Costs
Antineoplastic Agents
taxane

Keywords

  • Antineoplastic agents
  • Breast neoplasms
  • Costs
  • Docetaxel
  • Drug comparisons
  • Economics
  • Mortality
  • Paclitaxel
  • Pharmacoeconomics
  • Quality of life

ASJC Scopus subject areas

  • Pharmacology
  • Health Policy

Cite this

Cost-utility analysis of taxane therapy. / Yee, Gary C.

In: American Journal of Health-System Pharmacy, Vol. 54, No. SUPPL. 2, 01.01.1997, p. S11-S15.

Research output: Contribution to journalArticle

@article{65ab12d6128a41a8aa566aca3333ee8a,
title = "Cost-utility analysis of taxane therapy",
abstract = "A cost-utility analysis of docetaxel versus paclitaxel in patients with anthracycline-resistant metastatic breast cancer was reviewed. Cost-utility analysis provides estimates of the additional cost of a new therapy per quality-adjusted life-year (QALY) saved or gained. Utility scores measure the strength of a patient's preference for a given health state or outcome. Few studies have evaluated preferences in patients receiving cancer treatment. Since docetaxel may represent an advance in the management of anthracycline- resistant recurrent metastatic breast cancer, a decision-analysis model was developed to evaluate the pharmacoeconomics of this drug versus those of paclitaxel. Although the overall treatment costs of docetaxel were slightly higher than those of paclitaxel, docetaxel was associated with a gain of 0.0905 QALY per patient. This gain in QALYs is equivalent to 33 days of perfect health, which represents a substantial proportion of the life expectancy of one of these patients (typically no longer than nine months). The incremental cost-utility ratio associated with docetaxel therapy was estimated to be $4011 per QALY. Compared with paclitaxel, docetaxel for anthracycline-resistant metastatic breast cancer is within the acceptable range of cost-effectiveness ratios for most medical interventions. Cost- utility analysis is a valuable technique for evaluating new antineoplastic regimens that offer some treatment benefit but do not prolong survival compared with other therapeutic options.",
keywords = "Antineoplastic agents, Breast neoplasms, Costs, Docetaxel, Drug comparisons, Economics, Mortality, Paclitaxel, Pharmacoeconomics, Quality of life",
author = "Yee, {Gary C.}",
year = "1997",
month = "1",
day = "1",
language = "English (US)",
volume = "54",
pages = "S11--S15",
journal = "American Journal of Health-System Pharmacy",
issn = "1079-2082",
publisher = "American Society of Health-Systems Pharmacy",
number = "SUPPL. 2",

}

TY - JOUR

T1 - Cost-utility analysis of taxane therapy

AU - Yee, Gary C.

PY - 1997/1/1

Y1 - 1997/1/1

N2 - A cost-utility analysis of docetaxel versus paclitaxel in patients with anthracycline-resistant metastatic breast cancer was reviewed. Cost-utility analysis provides estimates of the additional cost of a new therapy per quality-adjusted life-year (QALY) saved or gained. Utility scores measure the strength of a patient's preference for a given health state or outcome. Few studies have evaluated preferences in patients receiving cancer treatment. Since docetaxel may represent an advance in the management of anthracycline- resistant recurrent metastatic breast cancer, a decision-analysis model was developed to evaluate the pharmacoeconomics of this drug versus those of paclitaxel. Although the overall treatment costs of docetaxel were slightly higher than those of paclitaxel, docetaxel was associated with a gain of 0.0905 QALY per patient. This gain in QALYs is equivalent to 33 days of perfect health, which represents a substantial proportion of the life expectancy of one of these patients (typically no longer than nine months). The incremental cost-utility ratio associated with docetaxel therapy was estimated to be $4011 per QALY. Compared with paclitaxel, docetaxel for anthracycline-resistant metastatic breast cancer is within the acceptable range of cost-effectiveness ratios for most medical interventions. Cost- utility analysis is a valuable technique for evaluating new antineoplastic regimens that offer some treatment benefit but do not prolong survival compared with other therapeutic options.

AB - A cost-utility analysis of docetaxel versus paclitaxel in patients with anthracycline-resistant metastatic breast cancer was reviewed. Cost-utility analysis provides estimates of the additional cost of a new therapy per quality-adjusted life-year (QALY) saved or gained. Utility scores measure the strength of a patient's preference for a given health state or outcome. Few studies have evaluated preferences in patients receiving cancer treatment. Since docetaxel may represent an advance in the management of anthracycline- resistant recurrent metastatic breast cancer, a decision-analysis model was developed to evaluate the pharmacoeconomics of this drug versus those of paclitaxel. Although the overall treatment costs of docetaxel were slightly higher than those of paclitaxel, docetaxel was associated with a gain of 0.0905 QALY per patient. This gain in QALYs is equivalent to 33 days of perfect health, which represents a substantial proportion of the life expectancy of one of these patients (typically no longer than nine months). The incremental cost-utility ratio associated with docetaxel therapy was estimated to be $4011 per QALY. Compared with paclitaxel, docetaxel for anthracycline-resistant metastatic breast cancer is within the acceptable range of cost-effectiveness ratios for most medical interventions. Cost- utility analysis is a valuable technique for evaluating new antineoplastic regimens that offer some treatment benefit but do not prolong survival compared with other therapeutic options.

KW - Antineoplastic agents

KW - Breast neoplasms

KW - Costs

KW - Docetaxel

KW - Drug comparisons

KW - Economics

KW - Mortality

KW - Paclitaxel

KW - Pharmacoeconomics

KW - Quality of life

UR - http://www.scopus.com/inward/record.url?scp=0031457265&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031457265&partnerID=8YFLogxK

M3 - Article

C2 - 9435927

AN - SCOPUS:0031457265

VL - 54

SP - S11-S15

JO - American Journal of Health-System Pharmacy

JF - American Journal of Health-System Pharmacy

SN - 1079-2082

IS - SUPPL. 2

ER -